Related Experiment Video
Updated: Aug 7, 2026

Optical Trapping of Nanoparticles
Published on: January 15, 2013
Nanomaterials functionalized signal-ON/OFF electrogenerated chemiluminescence biosensor for quantization of trypsin
Shuo Kang1, Ronghan Qu1, Yuhong Duan1
1Synthetic and Natural Functional Molecule Chemistry of Ministry of Education Key Laboratory, College of Chemistry and Materials Science, Northwest University, Xi'an, Shaanxi, 710127, People's Republic of China.
Abstract:
Trypsin (TPN) is an important proteolytic enzyme in the digestive system and its abnormal levels are indicative of some pancreatic diseases. As an endopeptidase, TPN can cleave substrate peptide mainly by catalyzing the hydrolysis of the carboxyl side peptide bond of lysine (K) or arginine (R) residues. Based on this hydrolysis cleavage effect, two kinds of nanomaterials functionalized electrogenerated chemiluminescence (ECL) biosensors for the determination of TPN were designed as follows: A signal-ON ECL biosensor was fabricated by attaching substrate peptide (HWR*GWVC, "*" representing the cleavage site, abbreviated as HGC) labeled with ferrocene carboxylic acid (as quencher) onto the surface of NH2-MIL-53(Al) film which was incorporated with ECL emitting species (bis (2,2'-bipyridine)-4'-methyl-4-carboxybipyridine-ruthenium (N-succinimidylester)-bis (hexafluorophosphate) (Ru complex)). The presence of tryptic cleavage event can eventually lead the Fc complex to leave the electrode and results in the increase of the ECL intensity. HGC labeled with Ru-Ti3C2Tx-AuNP complex was used as capture probe and signal probe, which was attached onto NH2-MIL-53(Al) film modified glassy carbon electrode. A signal-OFF ECL biosensor was built as described above. The presence of TPN lead the Ru-Ti3C2Tx-AuNPs to leave the electrode, which resulted in the decreasing ECL intensity. As expected, the fabricated ECL biosensing methods provide excellent sensitivity and selectivity toward the TPN activity. Thus, this strategy shows great potential application in the clinic for diagnosis of TPN-indicating diseases as well as the screening of TPN inhibitor-based anti-cancer drugs.

